The primary production site of erythropoietin (EPO) is shifted from the liver to the kidney shortly after birth. Under conditions of lost or reduced kidney production, it is valuable to measure the production capacity of the liver. However, there is a lack of urine or serum based methods that can distinguish endogenous EPO produced in different cell types. Here is presented a method based on chromatographic interaction with the lectin wheat germ agglutinin (WGA) that can distinguish presumably liver-produced EPO, found in anaemic patients receiving epoetin and darbepoetin, from kidney-produced EPO found in healthy individuals.
Introduction
EPO is a glycoprotein hormone responsible for the homeostatic regulation of red cell production, which is up-regulated by hypoxia through a recently described oxygen sensing mechanism [1, 2, 3] .
During fetal and early neonatal life, EPO is mainly produced in the liver [4] , and production is shifted to the kidney only shortly after birth. Adults seem to have retained a hepatic production capacity of up to 10% of total EPO during normal conditions. Patients with end-stage renal disease require life-long therapy with recombinant EPO (rhEPO), but currently, therapeutic approaches for enhancing endogenous non-renal production of EPO is of high interest, as discussed in recent reviews [5, 6] . Pharmacological manipulation of the hypoxia-inducible transcription factor (HIF) has been shown to stimulate endogenous EPO production [7] . Methods for up-regulating production of EPO from the liver seem especially attractive as an alternative to therapy with rhEPO when kidney production has ceased [8] .
Studies on EPO expression in specific tissues have required ablation of organs, followed by measurement of the remaining EPO production activity in blood, or directly in tissue extracts. The early studies of the liver-to-kidney shift were based on measuring total EPO levels (with bioassays and, subsequently, immunoassays) in response to anaemia in normal-and bilaterally nephrectomised fetal-and new-born sheep [9] . In studies on rats [10] , the expression level of EPO mRNA was measured in the respective organs. Measurement of EPO mRNA has shown that the rat liver can contribute with over 33% of the produced EPO during short-term severe hypoxia, and up to 37% after severe haemorrhage [11] . For humans, increased liver EPO production has been indicated for anephric patients during some pathologic conditions affecting the liver. EPO concentrations in blood and haemoglobin levels were both increased [12] . A study of haemodialysis patients found that anaemic patients showed improved haemoglobin levels during hepatic regeneration after hepatitis virus infection [13] .
There seems to be a common opinion that EPO expressed in different tissues, like that of kidney and liver, show no structural differences [5] . However, mammalian cells from different organs posttranslationally add a specific glycosylation signature to the produced glycoprotein [14] .
Glycoproteomics methods, distinguishing differently glycosylated protein subpopulations, can thus reveal the production site for a protein, without requiring extraction from organs, just by measurements in serum samples.
For EPO, which appears in very low concentrations, the advent of sensitive bioassays [15] and immunoassays [16] were required to allow studies of pathophysiology and diagnosing anaemia and polycythaemia. Shortly thereafter, a novel methodology, using sensitive EPO immunoassay for measuring the distribution of EPO glycoforms separated by electrophoresis, made it possible to distinguish the presence of differently charged isoform populations of EPO [17] . It was found that the liver-produced EPO in umbilical cord sera from new-born infants was distinguishable from serum EPO from adults, while rhEPO preparations showed a charge comparable to EPO in cord sera. Later on, the method proved to be useful for detecting illegal use of rhEPO in sports [18] .
Separation of protein glycoforms can also be performed with lectins, the carbohydrate binders that can distinguish several types of specific structures. A study measuring the interaction between EPO carbohydrate structures and lectins found that the lectin wheat germ agglutinin was especially useful for distinguishing recombinant and endogenous EPO [19] . The interaction between EPO and WGA has been used in a rapid lateral flow test for identification of rhEPO doping in humans and in horses [20, 21] .
The present study evaluates if the analytical method, based on WGA affinity chromatography, is capable to measure the presence of endogenous non-renal EPO glycoforms in urine samples from anaemic patients treated with rhEPO.
Design and Methods

Reagents and chemicals
The water used in all experiments was prepared using Milli-Q Academic equipment (Millipore, Billerica, MA, USA). Reagents, unless specified, were of analytical grade and purchased from Sigma (St. Louis, MO, USA). BSA was obtained from Intergen Company (NY, USA).
Recombinant human erythropoietin
The pharmaceutical glycoprotein Eprex®, (recombinant epoetin α) was purchased from JanssenCilag AB (Sollentuna, Sweden) and Neorecormon® (recombinant epoetin β) was obtained from Roche Diagnostics GmBH (Mannheim, Germany). One IU of these preparations corresponds to 8.4 and 8.3 ng recombinant EPO for Eprex and Neorecormon, respectively. Aranesp®, the recombinant EPO analogue darbepoetin α, was purchased from Amgen (Thousand Oak, CA, USA).
Determination of EPO concentration in urine in order to select samples for analysis
The EPO concentration in urine specimens was measured by a lateral flow immunoassay for EPO (MAIIA Diagnostics, Uppsala, Sweden), as described previously [22] . From the 38 tested samples with values in the range < 0.5 ng/L to 798 ng/L, 15 patient samples above 7.5 ng EPO/L were selected for a WGA chromatography analysis.
Urine specimens selected for affinity purification and chromatographic analysis
Urine specimens from 9 healthy volunteer donors (men and women between 20 and 60 years old) and from 15 patients receiving erythropoiesis stimulating agents (ESAs) were analysed. Seven of the patients were maintaining haemodialysis (HD), while the other patients came from a haematology clinic. The patients were subcutaneously (s.c.) injected at a rate from four times per week (4x w) to once every third week (3 rd w), with doses ranging from 2.000 to 30.000 IU (17-250 g) for epoetin, and from 20 to 150 g of darbepoetin α ( ng/L, 90% ESA) were affinity purified. The thawed urine specimens were gently turned end-overend to distribute the precipitations evenly, and 20 mL urine samples were pH corrected to a pH of 7-8. The urine mixture was passed through a 13 mm ø wide and 0.15 mm long anti-EPO monolith column (prototype kit from MAIIA Diagnostics, Uppsala, Sweden), and EPO was captured and eluted to a final volume of 0.24 mL, in accordance with a previous description [23] . The average recovery of EPO was 64 % for the 28 urine specimens. The affinity purified EPO was stored at -20° C until it was used for WGA separation.
WGA-Sepharose column
The WGA-Sepharose was prepared by reacting WGA (Medicago, Uppsala, Sweden) with NHSSepharose (GE Healthcare, Uppsala, Sweden) by adding 4.3 mg WGA to one mL of sedimented gel and proceeding in accordance with the instructions from the gel supplier.
Separation of EPO isoforms using WGA-Sepharose
About 1 mL of diluted sample containing 120-400 pg of anti-EPO affinity purified urine EPO was applied to a 0.9 mL HR 5/10 column of WGA-Sepharose, connected to an ÄKTAexplorer 10 automatic chromatography system (GE Healthcare, Uppsala, Sweden). The sample also contained and 1/500 protease inhibitor. The flow rate was 0.5 mL/min and sample application and washing with a starting buffer was performed during 7 minutes. The desorption gradient of competing sugar derivative was formed by mixing the starting buffer with the same buffer containing Nacetyl glucose amine (GlcNAc). A linear gradient from 0 to 15 mM GlcNAc was formed during 10 minutes, and 15 mM and 50 mM GlcNAc were applied during 2 and 3 minutes, respectively.
During the separation, 55 fractions with a volume of 0.35 mL were collected in microtiter wells. was kindly provided and used as described by the producer.
Lateral flow immunoassay for quantification of EPO
Calculations from the WGA-Sepharose chromatography
The desorption profile was obtained by calculating the percentage of EPO (%EPO) in each of the 55 collected fractions between 3.15 to 22.75 mL elution volumes, using the sum of the fractions for determination of total amount of EPO. The median elution volume (mL) that was required to elute 50 % of EPO was calculated for each sample.
Patient samples containing ESA were indicated by calculating the strong-to-medium WGA reacting EPO ratio (SWRE-ratio) by summing the % EPO for the elution volumes from 3 fractions ( (12.95-13.65 ).
Estimation of the percentage of non-normal EPO populations was performed by comparing the sample desorption profile with the generated profile with the best fit, obtained by mixing, in known proportions, the distribution values for the two endogenous EPO populations and for epoetin or darbepoetin.
Statistics
Values are means ± one standard deviation (SD) if not otherwise stated. Differences between groups were examined by Student´s t-test or Mann-Whitney test and statistical significance was accepted at P< 0.05.
Results
EPO desorption profile for wheat germ agglutinin (WGA) affinity chromatography
Endogenous urine EPO from healthy individuals, rhEPO (epoetin α and β), and the EPO analogue darbepoetin α all bound to the lectin ligand WGA, immobilized on a Sepharose column. During desorption, it was found that they showed different desorption profiles (see Fig. 1A ) when utilizing gradient elution with a low concentration of the competing sugar derivative GlcNAc. Fig.   1B shows the results from some of the patients. The majority of the patient samples showed EPO desorption profiles with a strong WGA binding, in accordance with the ESA used for treatment of their anaemia. However, some of the patients showed a form of EPO with weaker reaction to WGA compared to endogenous EPO from healthy individuals. The profile for EPO from a urine sample collected from patient 2 showed presence of both the weak WGA reacting EPO forms and injected darbepoetin. Table 1 shows the percentage of weak and strong reacting EPO populations, defined by the desorption profile, in the samples.
Identifying EPO populations by their median EPO elution volume
For endogenous EPO (n=9), epoetin preparations (n=5) and darbepoetin preparations (n=2), the median EPO elution volumes were 13.48 ± 0.23, 14.79 ± 0.35, 17.05 ± 0.20 (mL, mean ± SD), respectively (Fig. 2) . The epoetin and darbepoetin preparations were significantly (P<0.001) differentiated from endogenous EPO, as well as from each other.
The EPO chromatography results for the 15 patients receiving rhEPO or darbepoetin showed that 60% (9/15) of the ESA treated patients had median elution volumes above the 97.8% confidence limit (CL), indicating presence of ESA. Samples from 27% (4/15) of the patients had very low elution volumes (11.3 ± 0.12 mL, n=4), clearly deviating from both endogenous and recombinant EPO. However, for the results from the urine sample from patient 2, containing both weak reacting forms and darbepoetin, as shown in Fig. 1B , the median elution value indicated only the presence of ESA with a median elution value of 14.86 mL.
Identifying specific EPO populations by their weak or strong WGA reacting EPO ratios
It was clear, after analysing the urine specimen from patient 2, that presence of three different EPO populations in a sample required ratio-calculations at selected positions in the WGASepharose elution profile to describe the EPO population distribution. The presence of weak and strong WGA reacting EPO forms was estimated as a ratio relative to the normal endogenous EPO form. The best resolution was obtained when using the positions at 9.45 mL (weak reaction), 13.3 mL (normal endogenous form), and 19.6 mL (strong reaction) for calculation. The positions are indicated with arrows in Fig. 1B . The ratio results for both weak WGA reaction EPO (WWREratio) and strong WGA reaction EPO (SWRE-ratio) are found in Fig. 3 . Table 1 .
Weak WGA reacting forms appearing as the dominant EPO form (>50%) were found in the urine for patients 15, 14, 5, 12 and 2, having high WWRE-ratio values of 1.33 ± 0.27 (mean ± SD). 
Discussion
The presented method makes it possible to estimate the production site of EPO by measuring the interaction strength between the lectin WGA and the carbohydrate structures of EPO. EPO is rich in core fucosylated tetraantennary oligosaccharides [24] , and WGA is expected to bind to the terminal parts of the carbohydrate structures, especially the protruding polylactosamine structures [25] . Such structures are much more common in rhEPO than in endogenous EPO [24] . The stronger WGA interaction of rhEPO is in accordance with our results, as rhEPO required higher elution volume than endogenous EPO to pass the WGA column. The broad distribution profile after WGA chromatography for endogenous EPO is most probably due to the presence of a large number of glycosylated EPO forms with minor differences in their WGA affinity, in accordance with the 20-30 forms found when separating the isoforms due to charge [17] . EPO from different production sites have different proportions of WGA reacting isoforms, which can be measured as a shift in the median elution volume. In this study, several of the patient samples contained both weaker and stronger WGA reacting EPO, compared to the normal endogenous form, and calculation of the median elution volume may then result in a false classification. By calculating the weak-to-medium and strong-to-medium WGA reacting ratio for the EPO distribution, it was possible to correctly classify samples with three different populations of EPO as well. The obtained values were compared to the values from healthy individuals, and WWRE-ratio values above 97.8% CL classified the patient samples as containing deviating endogenous EPO while SWRE-ratios above 97.8% CL classified the patient samples as containing epoetin or darbepoetin.
It is well established that there is a remaining minor production in the liver in adulthood while most of the EPO, under normal conditions and in anaemia, is produced in the kidneys. The deviating weak WGA reacting endogenous EPO is most probably produced in the liver, which is the dominant non-renal production site. Also, the main source of EPO in the human fetus comes from the liver [9] , and EPO in umbilical cord serum has been found to have a different glycosylation, with more basic charge, compared to adult EPO [17, 26] . Two of the urine specimens from patients with deviating weak EPO forms, patient 5 and 15, showed also more basic EPO forms with an isoelectric point even higher than for rhEPO alpha and beta [26] .
Substantial EPO production from non-renal sources has also been shown in anephric subjects, both animals and humans [9, 12, 13] . The assumption that the deviating EPO is produced in the liver is supported by reports of an increased non-renal EPO production during proliferative repair of the liver [12, 13] , and high levels of EPO mRNA in the liver during hypoxia [11] . We therefore conclude that the deviating, weak reacting, non-renal endogenous EPO form distinguished in this study emanates from the liver.
Liver EPO was found in 53% (8/15) of the tested patient samples, measured as deviatingly high weak-to-medium WGA reacting EPO ratio. The low percentage, below 10%, of liver-produced EPO expected in samples from healthy individuals has not been possible to distinguish from kidney EPO in the desorption profile (Fig. 1) . The 8 patient samples had a higher percentage of liver EPO than the normal samples, and the main reason that it was possible to recognise liver EPO in the patient samples is due to their lack-, or low level, of kidney EPO. The 7 tested patients with severe renal impairment with maintenance haemodialysis were all producing liver EPO. It should be noted that only urine samples with a value above 7.5 ng EPO/L were selected for WGA chromatography, and for the 26 concentration-tested HD patients samples 27% were above 7.5 ng/L while 54% were below 3 ng/L. Among the 8 chromatography-tested haematological patients, only one showed presence of liver EPO.
Four samples contained 90-100% of liver EPO and in the range 8 to10 ng/L, which means that the liver EPO production was comparable to the kidney EPO production, with a median concentration of 8.5 ng/L, found in the urine from healthy individuals [22] . This indicates that the liver production can show more than a 20-fold increase, assuming 5 % liver EPO in the normal samples.
It seems that not all patients with renal failure or other anaemia can increase the non-renal EPO production, as 54% of the HD patients had EPO concentrations below 3 ng/L, compared to 7.5% of the samples from healthy individuals [22] . However, none of our patients had an EPO level in their urine that was adequate for the degree of anaemia (a severe anaemia without renal disease may increase EPO levels a 1000-fold), indicating a limitation in the ability to induce liver EPO production.
In 5 of the 15 patient samples of EPO, no exogenous EPO was detected, even though the patients had therapy with epoetin or darbepoetin. The reason for this is that the clearance of exogenous EPO is very rapid and samples were not taken immediately after injection.
Conclusion
This study shows that some patients with end-stage renal insufficiency can increase liver EPO production up to a total EPO concentration within the reference range for normal individuals, although this concentration is not adequate for the degree of anaemia.
By the use of WGA based EPO-specific glycoform analytical methods, it seems, for the first time,
to be possible to measure physiological and pathological shifts in EPO production sites. Such measurements can give answer to the question "Why not the liver instead of the kidney?" recently actualized in Blood [27] . Pharmacological treatment to enhance EPO production is a potential alternative to long term rhEPO treatment, and this method makes it possible to distinguish the enhanced EPO production rate for the liver and for the kidney. The arrows in panel B indicate the fractions that have been used to calculate ratios between weak (9.5 mL), medium (13.3 mL), and strong WGA (19.6 mL) interaction. 
